This document provides information about an electrochemiluminescence immunoassay for the qualitative detection of IgM antibodies to hepatitis B core antigen (anti-HBc IgM) in human serum and plasma.
The assay uses a μ-capture test principle involving two incubation steps. In the first step, samples are pretreated to block IgG antibodies. In the second step, ruthenium-labeled hepatitis B core antigen (HBcAg) and biotinylated anti-human IgM antibodies are added to the pretreated sample to form sandwich complexes which bind to streptavidin-coated microparticles.
The microparticles are then captured on an electrode surface and unbound substances are removed. Applying a voltage
This document provides information about an electrochemiluminescence immunoassay for the qualitative detection of IgM antibodies to hepatitis B core antigen (anti-HBc IgM) in human serum and plasma.
The assay uses a μ-capture test principle involving two incubation steps. In the first step, samples are pretreated to block IgG antibodies. In the second step, ruthenium-labeled hepatitis B core antigen (HBcAg) and biotinylated anti-human IgM antibodies are added to the pretreated sample to form sandwich complexes which bind to streptavidin-coated microparticles.
The microparticles are then captured on an electrode surface and unbound substances are removed. Applying a voltage
This document provides information about an electrochemiluminescence immunoassay for the qualitative detection of IgM antibodies to hepatitis B core antigen (anti-HBc IgM) in human serum and plasma.
The assay uses a μ-capture test principle involving two incubation steps. In the first step, samples are pretreated to block IgG antibodies. In the second step, ruthenium-labeled hepatitis B core antigen (HBcAg) and biotinylated anti-human IgM antibodies are added to the pretreated sample to form sandwich complexes which bind to streptavidin-coated microparticles.
The microparticles are then captured on an electrode surface and unbound substances are removed. Applying a voltage
This document provides information about an electrochemiluminescence immunoassay for the qualitative detection of IgM antibodies to hepatitis B core antigen (anti-HBc IgM) in human serum and plasma.
The assay uses a μ-capture test principle involving two incubation steps. In the first step, samples are pretreated to block IgG antibodies. In the second step, ruthenium-labeled hepatitis B core antigen (HBcAg) and biotinylated anti-human IgM antibodies are added to the pretreated sample to form sandwich complexes which bind to streptavidin-coated microparticles.
The microparticles are then captured on an electrode surface and unbound substances are removed. Applying a voltage
cobas e 411 11820567 119 100 cobas e 601 cobas e 602
English Reagents – working solution
System information The reagent rackpack (M, R1, R2) is labeled as A‑HBCIGM. For cobas e 411 analyzer: test number 460 M Streptavidin-coated microparticles (transparent cap), 1 bottle, 6.5 mL: For MODULAR ANALYTICS E170, cobas e 601 and cobas e 602 Streptavidin-coated microparticles 0.72 mg/mL; preservative. analyzers: Application Code Number 086 R1 Pretreatment anti‑HBc IgM (gray cap), 1 bottle, 10 mL: Intended use Sample pretreatment reagent: Anti‑human‑Fdγ‑antibody (sheep) Immunoassay for the in vitro qualitative determination of IgM antibodies to the > 0.05 mg/mL; phosphate buffer 100 mmol/L, pH 7.4; preservative. 2+ hepatitis B core antigen in human serum and plasma. R2 Anti-h-IgM-Ab~biotin; HBcAg~ Ru(bpy)3 (black cap), 1 bottle, 10 mL: The electrochemiluminescence immunoassay “ECLIA” is intended for use on Biotinylated monoclonal anti-h-IgM antibody (mouse) > 600 ng/mL; Elecsys and cobas e immunoassay analyzers. HBcAg (E. coli, rDNA), labeled with ruthenium complex > 200 ng/mL; phosphate buffer 100 mmol/L, pH 7.4; preservative. Note: Please note that the catalogue number appearing on the package insert retains only the first 8 digits of the licensed 11-digit Catalogue Number: A‑HBCIGM Cal1 Negative calibrator 1 (white cap), 2 bottles of 1.0 mL 11820567122 for the Anti-HBc IgM assay. The last 3 digits -122 have been each: replaced by -119 for logistic purposes. Human serum, preservative. Summary A‑HBCIGM Cal2 Positive calibrator 2 (black cap), 2 bottles of 1.0 mL each: References1,2,3,4,5,6,7,8,9,10 Anti‑HBc IgM (human) > 100 PEI-U/mLb) in human serum; Hepatitis B core antigen (HBcAg) is a non‑glycosylated protein (p22) which forms preservative. the nucleocapsid (virus core) of the hepatitis B virus. The virus core encloses the b) Paul‑Ehrlich‑Institute units HBV‑DNA (virus genome) and the DNA‑polymerase. In the cytosol of virus‑ producing hepatocytes the nucleocapsid is enveloped by the hepatitis B surface Precautions and warnings antigen (HBsAg) to form virions. Free HBcAg or non‑enveloped virus cores are For in vitro diagnostic use. not detectable in serum. Exercise the normal precautions required for handling all laboratory reagents. IgM antibodies to HBcAg occur in serum during proliferation of active hepatitis B Disposal of all waste material should be in accordance with local guidelines. virus and can still be detected weeks to months after viral proliferation has Safety data sheet available for professional user on request. ceased. High anti‑HBc IgM concentrations can be found in acute hepatitis B and This kit contains components classified as follows in accordance with the in attacks during chronic hepatitis B. Regulation (EC) No. 1272/2008: Tests for detecting anti‑HBc IgM antibodies are used, in conjunction with HBsAg n-Octyl-N,N-dimethyl-3-ammonio-1-propanesulfonate determinations, to identify acute hepatitis B viral infections. An acute attack of EUH 208 May produce an allergic reaction. hitherto non‑diagnosed chronic hepatitis B clinically resembles an acute hepatitis B infection and cannot be distinguished from this with certainty by determining the Product safety labeling follows EU GHS guidance. anti‑HBc IgM. Follow‑up studies, imaging procedures and liver biopsies are All human material should be considered potentially infectious. useful in differentiating between these two clinical pictures. The negative calibrator (A‑HBCIGM Cal1) has been prepared exclusively from Test principle the blood of donors tested individually and shown to be free from HBsAg and µ‑Capture test principle. Total duration of assay: 18 minutes. antibodies to HCV and HIV. The testing methods used assays approved by the FDA or cleared in compliance with the European Directive 98/79/EC, Annex II, 1st incubation: Pretreatment of 10 µL of sample (automatically prediluted 1:400 List A. with Diluent Universal) with anti‑Fdγ reagent to block specific IgG. Positive calibrator (A‑HBCIGM Cal2): Materials of human origin were tested for 2nd incubation: Biotinylated monoclonal h‑IgM‑specific antibodies, HBcAg HIV and hepatitis C. The findings were negative. The serum containing anti‑HBc labeled with a ruthenium complexa) and streptavidin-coated microparticles are IgM was inactivated using β‑propiolactone and UV‑radiation. added to the pretreated sample. Anti‑HBc IgM antibodies present in the sample react with the ruthenium‑labeled HBc antigen and the biotinylated anti‑h‑IgM However, as no inactivation or testing method can rule out the potential risk of to form a sandwich complex which becomes bound to the solid phase via infection with absolute certainty, the material should be handled with the same interaction of biotin and streptavidin. level of care as a patient specimen. In the event of exposure, the directives of the responsible health authorities should be followed.11,12 The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Avoid foam formation in all reagents and sample types (specimens, calibrators Unbound substances are then removed with ProCell/ ProCell M. Application of and controls). a voltage to the electrode then induces chemiluminescent emission which is Reagent handling measured by a photomultiplier. The reagents in the kit are ready‑for‑use and are supplied in bottles compatible Results are determined automatically by the software by comparing the with the system. electrochemiluminescence signal obtained from the reaction product of the cobas e 411 analyzer: The calibrators should only be left on the analyzer during sample with the signal of the cutoff value previously obtained by calibration. calibration at 20‑25 °C. After use, close the bottles as soon as possible and store a) Tris(2,2'-bipyridyl)ruthenium(II)-complex (Ru(bpy) 2+ 3 ) upright at 2‑8 °C. Due to possible evaporation effects, not more than 5 calibration procedures per bottle set should be performed. MODULAR ANALYTICS E170, cobas e 601 and cobas e 602 analyzers: Unless the entire volume is necessary for calibration on the analyzers,
2018-04, V 19a Can English 1/4
Anti-HBc IgM transfer aliquots of the ready‑for‑use calibrators into empty snap-cap bottles Materials required (but not provided) (CalSet Vials). Attach the supplied labels to these additional bottles. Store the REF 11876333122, PreciControl Anti‑HBc IgM, 16 x 1.0 mL aliquots at 2‑8 °C for later use. REF 11732277122, Diluent Universal, 2 x 16 mL sample diluent or Perform only one calibration procedure per aliquot. REF 03183971122, Diluent Universal, 2 x 36 mL sample diluent All information required for correct operation is read in from the respective reagent barcodes. REF 11776576322, CalSet Vials, 2 x 56 empty snap-cap bottles Please note: Both the vial labels, and the additional labels (if available) contain 2 General laboratory equipment different barcodes. The barcode between the yellow markers is for cobas 8000 MODULAR ANALYTICS E170 or cobas e analyzer systems only. If using a cobas 8000 system, please turn the vial cap 180° into the Accessories for cobas e 411 analyzer: correct position so the barcode can be read by the system. Place the vial on the instrument as usual. REF 11662988122, ProCell, 6 x 380 mL system buffer Storage and stability REF 11662970122, CleanCell, 6 x 380 mL measuring cell cleaning solution Store at 2‑8 °C. REF 11930346122, Elecsys SysWash, 1 x 500 mL washwater additive Do not freeze. REF 11933159001, Adapter for SysClean Store the Elecsys reagent kit upright in order to ensure complete availability of REF 11706802001, AssayCup, 60 x 60 reaction cups the microparticles during automatic mixing prior to use. REF 11706799001, AssayTip, 30 x 120 pipette tips Stability of the reagent rackpack REF 11800507001, Clean‑Liner Accessories for MODULAR ANALYTICS E170, cobas e 601 and unopened at 2‑8 °C up to the stated expiration date cobas e 602 analyzers: after opening at 2‑8 °C 8 weeks REF 04880340190, ProCell M, 2 x 2 L system buffer on cobas e 411 4 weeks REF 04880293190, CleanCell M, 2 x 2 L measuring cell cleaning solution on MODULAR ANALYTICS E170, 8 weeks REF 03023141001, PC/CC‑Cups, 12 cups to prewarm ProCell M and cobas e 601 and cobas e 602 CleanCell M before use REF 03005712190, ProbeWash M, 12 x 70 mL cleaning solution for run finalization and rinsing during reagent change Stability of the calibrators REF 03004899190, PreClean M, 5 x 600 mL detection cleaning solution unopened at 2‑8 °C up to the stated expiration date REF 12102137001, AssayTip/AssayCup, 48 magazines x 84 reaction cups or pipette tips, waste bags after opening at 2‑8 °C 8 weeks REF 03023150001, WasteLiner, waste bags on cobas e 411 at 20‑25 °C up to 5 hours REF 03027651001, SysClean Adapter M on MODULAR ANALYTICS E170, Accessories for all analyzers: use only once cobas e 601 and cobas e 602 at REF 11298500316, ISE Cleaning Solution/Elecsys SysClean, 20‑25 °C 5 x 100 mL system cleaning solution Assay Store calibrators upright in order to prevent the calibrator solution from adhering to the snap‑cap. For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator’s manual Specimen collection and preparation for analyzer‑specific assay instructions. Only the specimens listed below were tested and found acceptable. Resuspension of the microparticles takes place automatically prior to use. Read in Serum collected using standard sampling tubes or tubes containing separating the test‑specific parameters via the reagent barcode. If in exceptional cases the gel. barcode cannot be read, enter the 15‑digit sequence of numbers (except for the Li‑heparin, Na‑heparin, K2‑EDTA, K3‑EDTA, ACD, CPD, CP2D, CPDA and Na‑ cobas e 602 analyzer). citrate plasma. Do not use plasma treated with sodium fluoride and potassium MODULAR ANALYTICS E170, cobas e 601 and cobas e 602 analyzers: oxalate. PreClean M solution is necessary. Criterion: Correct assignment of negative and positive samples. Bring the cooled reagents to approximately 20 °C and place on the reagent disk Stable for 6 days at 2‑8 °C, 3 months at ‑20 °C. The samples may be frozen 5 (20 °C) of the analyzer. Avoid foam formation. The system automatically regulates times. the temperature of the reagents and the opening/closing of the bottles. The sample types listed were tested with a selection of sample collection tubes or Place the calibrators in the sample zone. systems that were commercially available at the time of testing, i.e. not all All the information necessary for calibrating the assay is automatically read into available tubes of all manufacturers were tested. Sample collection systems from the analyzer. various manufacturers may contain differing materials which could affect the test After calibration has been performed, store the calibrators at 2‑8 °C or discard results in some cases. When processing samples in primary tubes (sample (MODULAR ANALYTICS E170, cobas e 601 and cobas e 602 analyzers). collection systems), follow the instructions of the tube manufacturer. Calibration Centrifuge samples containing precipitates and thawed samples before performing the assay. Heat-inactivated samples may be used. Traceability: This method has been standardized against the “HBc Reference Serum 84 (anti‑HBc IgM)” of the Paul‑Ehrlich‑Institute, Langen (Germany). For Do not use samples and controls stabilized with azide. the Elecsys Anti‑HBc IgM assay, the cutoff (cutoff index 1.0) was set to Ensure the samples, calibrators and controls are at 20‑25 °C prior to approximately 100 PEI‑U/mL.13 measurement. Calibration frequency: Calibration must be performed once per reagent lot using Due to possible evaporation effects, samples and calibrators on the analyzers A‑HBCIGM Cal1, A‑HBCIGM Cal2 and fresh reagent (i.e. not more than 24 should be analyzed/measured within 2 hours. hours since the reagent kit was registered on the analyzer). The performance of the Elecsys Anti‑HBc IgM assay has not been established with cadaveric samples or body fluids other than serum and plasma. Materials provided See “Reagents – working solutions” section for reagents. 2 x 6 bottle labels
2/4 2018-04, V 19a Can English
Anti-HBc IgM Calibration interval may be extended based on acceptable verification of In rare cases, interference due to extremely high titers of antibodies to calibration by the laboratory. immunological components, streptavidin and ruthenium can occur. Renewed calibration is recommended as follows: For diagnostic purposes, the results should always be assessed in conjunction after 1 month (28 days) when using the same reagent lot with the patient’s medical history, clinical examination and other findings. after 7 days (when using the same reagent kit on the analyzer) Limits and ranges as required: e.g.: quality control findings with PreciControl Anti-HBc IgM outside Detection limit: ≤ 3.0 PEI‑U/mL the defined limits more frequently when this is required by pertinent regulations. The detection limit represents the lowest measurable analyte level that can be distinguished from zero. It is calculated as the value lying two standard deviations Range for the electrochemiluminescence signals (counts) for the calibrators: above that of the negative calibrator (negative calibrator + 2 SD, repeatability Negative calibrator (A‑HBCIGM Cal1): 600‑3500 (cobas e 411 analyzer), 400‑ study, n = 21). 3500 (MODULAR ANALYTICS E170, cobas e 601 and cobas e 602 analyzers). Dilution Positive calibrator (A‑HBCIGM Cal2): 24000‑150000 (cobas e 411 analyzer), Use Diluent Universal for automatic sample predilution. 18000‑130000 (MODULAR ANALYTICS E170, cobas e 601 and cobas e 602 analyzers). Expected values Quality control For the Elecsys Anti‑HBc IgM assay, the cutoff (cutoff index 1.0) was set to approximately 100 PEI‑U/mL. In acute HBV infections the anti‑HBc IgM level is For quality control, use PreciControl Anti‑HBc IgM. generally far above this limit. After recovery from hepatitis B disease the anti‑HBc Controls for the various concentration ranges should be run individually at least IgM levels are below this. Chronic hepatitis can produce values in the vicinity of once every 24 hours when the test is in use, once per reagent kit, and following the cutoff. each calibration. Specific performance data The control intervals and limits should be adapted to each laboratory’s individual Representative performance data on the analyzers are given below. Results requirements. Values obtained should fall within the defined limits. Each obtained in individual laboratories may differ. laboratory should establish corrective measures to be taken if values fall outside the defined limits. Precision If necessary, repeat the measurement of the samples concerned. Precision was determined using Elecsys reagents, human sera and controls. Follow the applicable government regulations and local guidelines for quality cobas e 411 analyzer control. Note: Repeatabilityc) Intermediate precisiond) For technical reasons re-assigned target values valid only for a specific reagent and control lot combination must be entered manually on all analyzers (except for Sample Mean SD CV Mean SD CV the cobas e 602 analyzer). Therefore always refer to the value sheet included in COIe) COI % COI COI % the reagent kit or PreciControl kit to make sure that the correct target values are used. HSf), negative 0.123 0.003 2.2 0.069 0.002 2.8 When a new reagent or control lot is used, the analyzer will use the original HS, weakly positive 1.14 0.040 3.5 1.15 0.021 1.8 values encoded in the control barcodes. Calculation HS, positive 3.58 0.131 3.7 3.98 0.135 3.4 The analyzer automatically calculates the cutoff based on the measurement of A‑ PCg) A‑HBCIGM1 0.053 0.001 1.7 0.063 0.002 3.3 HBCIGM Cal1 and A‑HBCIGM Cal2. PC A‑HBCIGM2 1.39 0.063 4.5 1.55 0.056 3.6 The result of a sample is given either as reactive or non-reactive as well as in the form of a cutoff index (signal sample/cutoff). c) Repeatability = within-run precision (n = 20/21) Interpretation of the results d) Intermediate precision = between-run precision (n = 10) e) COI = cutoff index Samples with a cutoff index ≥ 1.0 are reactive in the Elecsys Anti‑HBc IgM assay. These samples are considered positive for anti‑HBc IgM. f) HS = human serum Samples with a cutoff index < 1.0 are non‑reactive in the Elecsys g) PC = PreciControl Anti‑HBc IgM assay. These samples are considered negative. MODULAR ANALYTICS E170, cobas e 601 and cobas e 602 analyzers Note: According to the recommendations of the Paul‑Ehrlich‑Institute, Langen (Germany), an equivocal range should be allowed for the assessment of results Repeatabilityc) Intermediate precisioni) from anti‑HBc IgM tests. For the Elecsys Anti‑HBc IgM assay the equivocal cutoff index range is Sample Mean SD CV Mean SD CV 0.9‑1.1. COI COI % COI COI % Limitations - interference HS, negative 0.037 0.001 3.4 0.037 0.002 3.9 The assay is unaffected by icterus (bilirubin < 428 µmol/L or < 25 mg/dL), hemolysis (Hb < 1.2 mmol/L or < 2.0 g/dL), lipemia (Intralipid HS, weakly positive 1.32 0.032 2.4 1.33 0.054 4.1 < 1500 mg/dL) and biotin (< 409 nmol/L or < 100 ng/mL). Criterion: Correct assignment of negative and positive samples. HS, positive 4.91 0.080 1.6 5.11 0.171 3.3 Samples should not be taken from patients receiving therapy with high biotin PC A‑HBCIGM1 0.032 0.001 1.5 0.042 0.001 1.9 doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration. PC A‑HBCIGM2 1.67 0.043 2.6 1.80 0.069 3.8 As with many μ‑capture assays, an interference with unspecific human IgM is h) Intermediate precision = within-laboratory (modified protocol (EP5-A) of the CLSI (Clinical and observed. Increasing amounts of unspecific human IgM may lead to a decrease in Laboratory Standards Institute): 6 times daily for 10 days (n = 60)) the recovery of positive samples with the Elecsys Anti‑HBc IgM assay. Analytical specificity No interference was observed from rheumatoid factors up to a concentration of No cross-reactions with HAV, HCV, HIV 1+2, CMV, EBV, HSV, E. coli, 4200 IU/mL. Toxoplasma gondii, Rubella, and Treponema pallidum were observed. In vitro tests were performed on 19 commonly used pharmaceuticals. No interference with the assay was found.
990/1003 were negative with a comparison test (98.7 % specificity).
242/242 samples from hospitalized patients, pregnant women, and dialysis patients with no indication of a HBV infection were negative with both the Elecsys Anti‑HBc IgM assay and the comparison test (100 % specificity for this cohort). References 1 Gudat F, Bianchi L, Sonnabend W, et al. Pattern of core and surface expression in liver tissue reflects state of specific immune response in hepatitis B. Laboratory investigations 1975;32(1):1-9. 2 Gerlich WH, Robinson WS. Hepatitis B virus contains protein attached to the 5’ terminus of its complete DNA strand. Cell 1980;21:801-809. 3 Gerlich WH, Goldmann U, Müller R, et al. Specificity and localization of the hepatitis B virus-associated protein kinase. Journal of Virology 1982;42(3):761-766. 4 Roossinck MJ, Siddiqui A. In vivo phosphorylation and protein analysis of hepatitis B virus core antigen. J Virol 1987;61:955-961. 5 Gallina A, Bonelli F, Zentilin L, et al. A recombinant hepatitis B core antigen polypeptide with the protamine-like domain deleted self- assembles into capsid particles but fails to bind nucleic acids. J Virol 1989;63(11):4645-4652. 6 Zhou S, Stranding DN. Hepatitis B virus capsid particles are assembled from core-protein dimer precursors. Proc Natl Acad Sci USA 1992;89:10046- 10050. 7 Birnbaum BS, Nassal M. Hepatitis B virus nucleocapsid assembly: primary structure requirements in the core protein. J Virol 1990;64(7):3025-3330. 8 Hollinger FB. Hepatitis B virus. In Fields BN, Knipe DM (eds) Virology 2nd ed., New York, Raven Press 1990:2171-2236.